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ARTICLE

The phosphodiesterase-4 inhibitor rolipram
reverses Ab-induced cognitive impairment
and neuroinﬂammatory and apoptotic
responses in rats
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Abstract
b-amyloid (Ab) peptides play an important role in cognition deﬁcits, neuroinﬂammation, and apoptosis
observed in Alzheimer’s disease (AD). Activation of cyclic AMP (cAMP) signalling enhances memory
and inhibits inﬂammatory and apoptotic responses. However, it is not known whether inhibition
of phosphodiesterase-4 (PDE4), a critical controller of intracellular cAMP concentrations, aﬀects
AD-associated neuroinﬂammatory and apoptotic responses and whether these responses contribute to
deﬁcits of memory mediated by cAMP signalling. We addressed these issues using memory tests and
neurochemical measures. Speciﬁcally, rats microinfused with aggregated Ab25-35 (10 mg/side) into
bilateral CA1 subregions displayed deﬁcits in learning ability and memory, as evidenced by decreases in
escape latency during acquisition trials and exploratory activities in the probe trial in the water-maze
task and 24-h retention in the passive avoidance test. These eﬀects were reversed by rolipram (0.1, 0.25
and 0.5 mg/kg.d i.p.), a prototypic PDE4 inhibitor, in a dose-dependent manner. Interestingly, Ab25-35treated rats also displayed decreases in expression of phosphorylated cAMP response-element binding
protein (pCREB) and Bcl-2, but increases in expression of NF-kB p65 and Bax in the hippocampus ; these
eﬀects were also reversed by rolipram in a dose-dependent manner. Similar neurochemical results were
observed by replacing Ab25-35 with Ab1-42, a full-length amyloid peptide that quickly forms toxic
oligomers. These results suggest that PDE4 inhibitors such as rolipram may reverse Ab-induced memory
deﬁcits at least in part via the attenuation of neuronal inﬂammation and apoptosis mediated by cAMP/
CREB signalling. PDE4 could be a target for treatment of memory loss associated with AD.
Received 13 December 2010 ; Reviewed 6 January 2011 ; Revised 7 April 2011 ; Accepted 3 May 2011 ;
First published online 9 June 2011
Key words : CREB, memory, phosphodiesterase-4 (PDE4), rolipram, b-amyloid (Ab).

Introduction
Alzheimer’s disease (AD) is a multifaceted neurodegenerative disorder of the central nervous system
characterized by progressive cognitive dysfunction.
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It has been considered that excessive accumulation of
neurotoxic b-amyloid peptide (Ab) in the brain is the
hallmark of AD ; deposition of Ab causes neuropathological lesions in the brain of patients with AD
(Hardy, 1997 ; Selkoe, 2000 ; Suh & Checler, 2002).
While mechanisms by which Ab induces neuronal
cell death remain unclear, results from accumulating
studies suggest that Ab may cause neurotoxicity via :
(1) formation of reactive oxygen species (Barnham et al.
2004 ; Hardy & Selkoe, 2002), (2) intracellular calcium
accumulation (Demuro et al. 2010), (3) changes in
membrane ﬂuidity (Yang et al. 2010), (4) energy
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transgenic mice (Gong et al. 2004). Drugs that inhibit
PDE4 have received a great deal of attention, partially
due to their inhibitory eﬀects on inﬂammation
(Genain et al. 1995 ; Sekut et al. 1995 ; Souness et al.
2000 ; Teixeira et al. 1997) and apoptosis (Sousa et al.
2010) in various models. However, it is not clear
whether PDE4 inhibitors block Ab-induced inﬂammatory responses and apoptosis, important mechanisms in the pathogenesis of AD (Agostinho et al. 2010 ;
Lukiw & Bazan, 2010).
The fraction 25-35 of Ab (Ab25-35), which is the
neurotoxin core fragment of the full-length Ab peptide
(Cheng et al. 2006 ; Pike et al. 1993), plays a pivotal
role in the neurodegenerative process of AD. Central
administration of Ab25-35 produces cognitive deﬁcit
(Cheng et al. 2010 ; Lin et al. 2009), cholinergic dysfunction (Olariu et al. 2001), neuronal apoptosis
(Ruan et al. 2010), oxidative stress (Ahn et al. 2006 ;
Um et al. 2006), and neuroinﬂammation (Lin et al.
2009). Speciﬁcally, microinfusions of Ab25-35 into the
hippocampus impair memory in various tasks, including the Morris water-maze and passive avoidance
tests in mice (Kim et al. 2008 ; Maurice et al. 1996 ; Wang
et al. 2001) and rats (Cheng et al. 2010 ; Lin et al. 2009)
and the radial-arm maze and social recognition tests in
rats (Delobette et al. 1997 ; Jin et al. 2004 ; Stepanichev
et al. 2003 ; Sun & Alkon, 2002). Recently, our studies
have shown that infusions of Ab1-40 into the hippocampus cause memory impairment via decreases in
cAMP/CREB signalling (Cheng et al. 2010). Similar
eﬀects of Ab1-42 on memory and cAMP signalling
have also been observed (Malm et al. 2006 ; O’Hare et al.
1999 ; Tong et al. 2001 ; Vitolo et al. 2002). Given that
Ab25-35 increases inﬂammatory factors such as IL-1b,
IL-6, and TNF-a in the hippocampus (Lin et al. 2009), it
was of interest to know whether the inﬂammatory and
apoptotic eﬀects of Ab25-35 in the brain contribute to
deﬁcits of memory and whether pharmacologically
induced up-regulation of pCREB reversed Ab25-35induced neuronal inﬂammation, apoptosis, and
memory deﬁcits. Ab1-42 was also used to verify the
eﬀects of rolipram on Ab-induced neurochemical
changes in the brain.

Materials and methods
Animals
Adult male Sprague–Dawley rats (Laboratory Animal
Centre of Southern Medical University, China or
Harlan, USA), weighing 250–300 g, were used for the
experiments. Animals were housed in a temperaturecontrolled room (21¡2 xC) on a 12-h light/dark cycle
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depletion (Dhitavat et al. 2002), (5) alteration of cytoskeleton components (Lesort et al. 1997), and (6) inﬂammatory responses (Agostinho et al. 2010). These
neuropathological changes are closely linked to
chronic inﬂammation and apoptosis, which are highly
correlated with the early stage of AD via increased
markers of inﬂammatory and apoptotic responses
(Luterman et al. 2000 ; Mehlhorn et al. 2000 ; Mrak &
Griﬃn, 2001 ; Parachikova et al. 2007 ; Pasinetti, 2001).
Moreover, drugs with anti-inﬂammatory activity
reduce progression of cognitive deﬁcits and/or Ab
burden in animal models of AD (Jantzen et al. 2002 ;
Lim et al. 2000 ; Townsend & Praticò, 2005). Thus,
therapeutic eﬀorts aimed at interruption of Ab-induced
neuroinﬂammation and apoptosis may be beneﬁcial in
AD.
Intracellular cyclic AMP (cAMP) signalling has
been well established in the mediation of memory
(Bailey et al. 1996 ; Barad et al. 1998 ; Li et al. 2011 ;
Zhang et al. 2000). Cyclic AMP activates protein kinase
A (PKA), which phosphorylates and activates the
subsequent downstream target cAMP-response element binding (CREB) protein (Lonze & Ginty, 2002 ;
Zhang, 2010). This signalling cascade is important
for mediating memory, in particular hippocampusdependent long-term memory (Tully et al. 2003) ; activation of cAMP signalling increases synaptic plasticity
and produces memory-enhancing eﬀects in rodents
(Barad et al. 1998 ; Li et al. 2011 ; Zhang et al. 2000, 2004,
2005). In addition, increases in cAMP levels during
inﬂammation inhibit production of pro-inﬂammatory
cytokines and stimulate formation of IL-10, an antiinﬂammatory factor (Kast, 2000 ; Szelenyi et al. 2000).
Further, while elevation of cAMP triggers apoptosis in
cancer cells (Naviglio et al. 2009), it prevents development of apoptotic machinery in neurons and neutrophils (De et al. 1994 ; Parvathenani et al. 1998).
Therefore, cAMP signalling may play a beneﬁcial
role in regulating Ab peptide-induced inﬂammatory
responses and apoptosis in vivo.
Phosphodiesterase-4 (PDE4), an enzyme that
speciﬁcally hydrolyses cAMP, plays an important role
in the mediation of learning and memory. Administration of PDE4 inhibitors such as rolipram
enhances memory (Barad et al. 1998 ; Li et al. 2011 ;
Rutten et al. 2006) and reverses memory deﬁcits induced by pharmacological (Zhang & O’Donnell, 2000 ;
Zhang et al. 2000, 2004, 2005), physical (Imanishi et al.
1997), physiological (Vecsey et al. 2009), or genetic
(Bourtchouladze et al. 2003) manipulations. Rolipram
treatment also reverses memory deﬁcits induced by
Ab25-35 or Ab1-40 (Cheng et al. 2010) or observed in
amyloid precursor protein (APP)/presenilin-1 (PS1)

Rolipram and Ab25-35 eﬀects
MWM
VPT

Day 0

1

12
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Fig. 1. Schedule of drug treatment and test orders. Rolipram (0.1, 0.25, or 0.5 mg/kg) or its vehicle (0.9 % saline containing
10 % DMSO) was injected i.p. 24 h after Ab25-35 (10 mg/side) or its vehicle, which was infused into bilateral CA1 subregions
12 d before the beginning of the 3-d visible platform test (VPT) in the Morris water-maze (MWM). On day 15, the water-maze
acquisition trials (AT) were conducted four times a day for 5 consecutive days, followed by the probe trial test (PT) 24 h after
the last acquisition trial. On day 21, habituation (H) of the passive avoidance chamber was performed, followed the next day
by the training trial (Tr), the 3-h retention test (RT), and 24 h after initial training, another retention test (RT) for measuring
long-term memory. Animals were sacriﬁced (Sac) 24 h after the last behavioural test. Rolipram or its vehicle was injected
once per day for 24 d, 1 h prior to each test or sacriﬁce.

(lights on 06:00 hours), with water and food available
ad libitum. All experiments were performed according
to NIH Guide for the Care and Use of Laboratory
Animals (NIH Publications No. 80–23, revised, 1996).
The procedures were approved by the Animal Care
and Use Committees of the Southern Medical University, China, and West Virginia University Health
Sciences Center, USA.
Drugs
Ab25-35 (Beijing Guo Ding Technology Ltd, China),
Ab1-42 (rPeptide, USA), or Ab42-1 (rAb42-1 ;
GenScript, USA) was dissolved in 0.9 % sterile saline
or artiﬁcial cerebrospinal ﬂuid (aCSF) containing 35 %
acetonitrile and 0.1 % triﬂuoroacetic acid (Cheng et al.
2010) at a ﬁnal concentration of 4 mg/ml (for Ab25-35)
or 0.4 mg/ml (for Ab1-42 and Ab42-1) and incubated at
37 xC for 4 d to form aggregated Ab (Delobette et al.
1997 ; Pike et al. 1993) before use. Rolipram (SigmaAldrich, USA) was dissolved in 0.9 % saline containing
10 % or 1 % dimethyl sufoxide (DMSO ; for tests involving Ab25-35 and Ab1-42/Ab42-1, respectively) ;
the injection volume for peripheral administration
was 1 ml/kg.

coordinates : AP x3.3 mm from Bregma ; ML 2.0 mm
from the midline ; DV x2.5 mm from dura (Paxinos &
Watson, 1986 ; Zhang et al. 2004). Ab25-35 (10 mg in
2.5 ml/side ; at this volume the Ab25-35 solution
was suﬃciently thin for infusions ; Cheng et al. 2010),
Ab1-42 or Ab42-1 (0.4 mg in 1 ml/side for both peptides), or vehicle [0.9 % saline (for Ab25-35) or aCSF
(for Ab1-42 or Ab42-1) containing 35 % acetonitrile and
0.1 % triﬂuoroacetic acid] in the same, corresponding
volumes was infused bilaterally at the rate of 0.5
(for Ab25-35) or 0.25 (for Ab1-42 or Ab42-1) ml/min
using a syringe pump ; the 28-gauge infusion
cannulae were left in place for additional 5 min
to permit diﬀusion before the animals were returned
to their home cages. No ﬂocculation of peptides
was observed during infusions. The dose of Ab25-35
or Ab1-42/Ab42-1 was chosen based on our preliminary or published studies ; the latter have shown
that Ab25-35 centrally administered at a similar dose
impairs memory (Cheng et al. 2010) and produces
inﬂammatory responses in the brain (Lin et al. 2009).
The injection sites were veriﬁed histologically
after completion of behavioural tests (Zhang et al.
2004).
Behavioural test procedures

Surgery
Rats were anaesthetized with intraperitoneal (i.p.) administration of ketamine (100 mg/kg) and xylazine
(10 mg/kg) before they were placed in a stereotaxic
apparatus (Stoelting, USA). Guide cannulae (22gauge, 6 mm ; Plastics One, USA) were implanted into
bilateral CA1 subregions using the following

To examine the eﬀect of rolipram on Ab25-35-induced
memory deﬁcits, ﬁve groups of 12 rats each were
tested for memory using Morris water-maze and
passive avoidance tasks (Fig. 1) : (a) saline+vehicle
(10 % DMSO for rolipram) ; (b) Ab25-35+vehicle ;
(c) Ab25-35+rolipram (0.1 mg/kg) ; (d) Ab2535+rolipram (0.25 mg/kg) ; (e) Ab25-35+rolipram
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Academy of Medical Sciences, China). The acquisition
training consisted of four trials each day for ﬁve consecutive days.
Twenty-four hours after the last acquisition trial
(i.e. day 20), the probe trial test was conducted with
the platform removed. Each rat was placed into the
pool at one ﬁxed start position and allowed to swim
freely for 90 s. The distance swum, entries and time
spent in the target quadrant (i.e. the previous location
of the platform), and the mean swimming speed were
recorded.

Morris water-maze test
This was performed as described previously (Morris,
1984 ; Zhang et al. 2008) with some modiﬁcations.
The apparatus consisted of a circular pool (120 cm diameter, 50 cm height) ﬁlled with water (23¡1 xC and
32 cm depth), which was opaque by mixing with milk
powder, and a platform (10 cm diameter), which was
either visible (in the visible platform test) or immersed
2 cm under the surface of the water (in the acquisition
training) in one of the four identical quadrants.
The pool was placed in a room illuminated at 100 lx
containing several extra-maze cues. Twelve days after
infusions of Ab25-35 the visible platform test was
performed, during which the escape latency (time required to locate and climb onto the platform) of
each rat was determined using the visible platform
(1 cm above the water surface). The test was conducted once per day for three consecutive days ; rats were
placed in the pool each day from diﬀerent starting
points selected randomly. Rats that failed to ﬁnd the
platform within 90 s were guided to the platform
manually.
Twenty-four hours after the last trial of the visible
platform test, acquisition training was performed ; the
platform was moved to another quadrant and ﬁxed
there throughout the acquisition trials. Rats were individually placed in the water facing the wall of the
pool in order to negate any directional inﬂuence. Each
rat was allowed to escape by swimming to the platform ; the escape latency was recorded with the cut-oﬀ
time 90 s. If the animal failed to locate the platform
within 90 s, it was gently guided to the platform
and allowed to stay on it for 30 s. Following completion of each trial, animals were dried gently with
paper towel and kept warm under heat lamps in
holding cages for 5 min before they were returned to
their home cages. Swimming behaviours, including
escape latency, distance swum, swimming speed, and
swimming paths, were monitored using a computercontrolled video-tracking system (CG-400 Image Acquisition System, Institute of Materia Medica, Chinese

Passive avoidance test
This was performed using the step-through passive
avoidance apparatus (Institute of Materia Medica,
Chinese Academy of Medical Sciences, China), following procedures described previously (Li et al. 2011 ;
Zhang et al. 2000) with minor modiﬁcations. The apparatus consisted of a chamber with two compartments (dark/illuminated), which were connected by a
guillotine door. The dark compartment had a
stainless-steel grid ﬂoor available for electric footshocks. All rats were given a habituation session,
during which they were allowed to freely explore the
apparatus for 4 min. Twenty-four hours later, the
training trial was performed. Rats were individually
placed in the illuminated compartment for 60 s before
the door was lifted. Immediately after the rat entered
the dark compartment, the door was closed and an
inescapable electric shock (0.5 mA, 3 s) was delivered.
The rat was then returned to the home cage. The retention test was performed 3 h and 24 h after training
to measure short-term and long-term memory, respectively. The latency was recorded following the
same procedures as in the acquisition trial, but no
footshock was delivered. The cut-oﬀ time was 300 s.
Western blot analysis
Twenty-four hours after the passive avoidance test
(for Ab25-35) or 14 d after Ab1-42 or Ab42-1 microinfusions and 1 h after the last rolipram injection, rats
were decapitated, and the hippocampus dissected and
stored at x80 xC until analysis. Hippocampal tissues
were homogenized in ice-cold RIPA buﬀer containing
0.1 % phenylmethylsulfonyl ﬂuoride and assessed for
expression of pCREB, NF-kB, Bcl-2, and Bax proteins.
Each sample was separated by electrophoresis in 12 %
polyacrylamide gels (120 V, 150 min) before being
transferred to PVDF membranes (60 V, 180 min). Nonspeciﬁc bindings were blocked with 5 % BSA for 2 h.
After washing, membranes were subsequently
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(0.5 mg/kg). Twenty-four hours after microinfusions
of Ab25-35 (10 mg/side) or saline into bilateral CA1
subregions in the hippocampus, rats were injected
(i.p.) with diﬀerent doses of rolipram or its vehicle,
once per day for 12 d prior to the beginning of watermaze training and probe trial testing ; the animals
were then subjected to passive avoidance habituation,
training, and testing. Rolipram treatment was given
1 h before and continued throughout the behavioural
tests.

Rolipram and Ab25-35 eﬀects

Statistical analysis
Data shown are expressed as means¡S.E.M. All the
data were analysed using one-way ANOVA followed
by Newman–Keuls tests for post-hoc comparisons
between groups, with the exception of the data of the
water-maze acquisition trials, which were analysed
by two-way repeated-measures ANOVA. Statistical
signiﬁcance was considered when p<0.05.

Results
Rolipram reversed memory impairment induced
by Ab25-35 in Morris water-maze and passive
avoidance tasks
To establish memory deﬁcits produced by Ab25-35,
we examined memory performance in rats microinfused with aged Ab25-35 at 10 mg/side into CA1
using the water-maze and passive avoidance tests.
Histological veriﬁcation showed that the cannula
placements were highly localized in hippocampal CA1
subregions (data not shown). In addition, there were
no visible inﬂammatory changes at the site of injections (i.p.) during the period of rolipram/vehicle administration. In order to evaluate the animals’ abilities
of vision and motor activity, navigation to a visible
platform was performed before the hidden platform
procedures in the water-maze test. While the escape
latency to the visible platform varied with diﬀerent
treatments, no signiﬁcant changes were observed in
any of the treatment groups during the 3-d testing
[F(4,110)=1.724, p=0.158 ; Fig. 2a], suggesting that

neither surgery nor drug treatment altered vision
ability or general motor activity.
During the 5-d acquisition trials in the water-maze
test, all the rats, regardless of the diﬀerent treatments,
displayed progressive decreases in escape latency to
reach the hidden platform. Two-way repeatedmeasures ANOVA revealed signiﬁcant changes in
drug eﬀect [F(4, 1045)=58.63, p<0.0001] and time
eﬀect [F(19, 1045)=67.46, p<0.0001], but not for
drugrtime interaction [F(76, 11045)=1.184, p=0.141 ;
Fig. 2b]. Post-hoc Newman–Keuls comparisons indicated that Ab25-35, administered 15 d prior to the
beginning of acquisition training, increased escape
latencies on sessions 3–10, 13, 14, 16, and 18 compared
to the corresponding vehicle controls (p<0.05, 0.01, or
0.001 ; Fig. 2b) ; these were reversed by rolipram
at diﬀerent doses (0.1 mg/kg for sessions 3–7 ;
0.25 mg/kg for sessions 3–4, 7–10 ; 0.5 mg/kg for
sessions 3–10, 16 ; p<0.05, 0.01, or 0.001). In addition,
the rats also displayed slight, progressive decreases
in swimming speed over time. Two-way repeatedmeasures ANOVA revealed signiﬁcant changes in
drug eﬀect [F(4, 1045)=3.53, p=0.01] and time eﬀect
[F(19, 1045)=9.44, p<0.0001], but not for drugrtime
interaction [F(76, 1045)=1.004, p=0.47 ; Fig. 2c]. Posthoc Newman–Keuls comparisons indicated that Ab2535, with or without rolipram treatment, did not alter
swimming speed compared to the corresponding vehicle controls.
Twenty-four hours after the last acquisition trial
(i.e. 20 d after Ab25-35 infusions or 19 d after the beginning of rolipram treatment), rats were tested for
spatial memory in the probe trial test, during which
the platform was removed. The total distance swum
during the probe trial test was not diﬀerent between
groups (data not shown). Drug treatment altered
entries [F(4, 55)=5.35, p=0.001 ; Fig. 2d], duration
[F(4, 55)=17.77, p<0.0001 ; Fig. 2e], and distance
swum [F(4, 55)=6.37, p=0.0003 ; Fig. 2f] in the target
quadrant. Post-hoc Newman–Keuls tests indicated
that Ab25-35 decreased entries (p<0.01), duration
(p<0.001), and distance (p<0.001) compared to the
respective vehicle controls ; these were reversed by
chronic treatment with rolipram in a dose-dependent
manner (p<0.05, 0.01, or 0.001 ; Fig. 2d–f ). In contrast,
swimming speed was not altered by any of the drugs
[F(4, 55)=0.296, p=0.879 ; Fig. 2g], indicating that
changes in spatial memory measured in the probe
trial were independent of general motor activity.
Consistent with this, the behavioural tracking results
revealed that both vehicle- and Ab/rolipram-treated
rats displayed more exploration in the target quadrant
than the rats treated with Ab25-35 alone (Fig. 2h) ; this
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incubated with respective primary antibodies for
rabbit anti-phospho-CREB [Ser133 ; 1 : 1000 ; CST
(Shanghai) Biological Reagents Company Ltd, or
Millipore, USA (for tests involving Ab1-42)], anti-NFkB p65 [1 : 1000 ; Abcam (Hong Kong) Ltd, or Millipore,
USA (for tests involving Ab1-42)], anti-Bcl-2 (1 : 1000),
anti-Bax [1 : 1000, CST (Shanghai) or Millipore, USA
(for tests involving Ab1-42)], anti-GAPDH [1 : 1000,
Abcam (Hong Kong) Ltd], and anti-b-actin (Abcam,
USA) at 4 xC overnight. Membranes were then incubated for 1 h with secondary antibodies [1 : 10 000 ;
Abcam (Hong Kong) Ltd]. The detection and quantiﬁcation of speciﬁc bands were developed using enhanced chemiluminescence reagent (Millipore, USA),
visualized and analysed using Kodak X-Omat ﬁlm
and ‘ Image-Pro ’ software (www.scioncorp.com) or
a ﬂuorescence scanner (Odyssey Infrared Imaging
System, Li-Cor Biotechnology, USA, for tests involving Ab1-42).
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Fig. 2. Eﬀects of rolipram on Ab25-35-induced spatial cognitive deﬁcits in the water-maze test in rats. (a) Escape latency was
not signiﬁcantly changed by drug treatment during the 3-d visible platform test. (b, c) Changes in (b) escape latency to reach
the hidden platform and (c) swimming speed during the 5-d acquisition trials. Ab25-35 overall increased escape latency,
which was reversed by rolipram, but did not alter swimming speed. (d–g) Eﬀects of Ab25-35 with or without rolipram on
(d) entries, (e) duration, (f) distance swum in the target quadrant, and (g) mean swimming speed in the probe trial test
performed 24 h after the last acquisition trial. Ab25-35 decreased the entries, duration, and swimming distance in the target
quadrant, which were all reversed by rolipram (0.1, 0.25, or 0.5 mg/kg) in a dose-dependent manner, whereas the swimming
speed was not changed by drug treatment. (h) Representative searching swimming paths by rats with diﬀerent treatments in
the probe trial test. While vehicle control animals swam concentrating on the target quadrant, Ab-treated rats swam
primarily around the pool ; this was reversed by rolipram treatment. Rolipram was injected i.p. once a day for 12–20 d during
the water-maze test, starting 24 h after microinfusion of Ab25-35 (10 mg/side) into bilateral CA1 subregions. Values represent
means¡S.E.M. (n=12 per group) ; * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle controls (Veh+Veh) ; # p<0.05, ## p<0.01,
###
p<0.001 vs. Ab25-35+vehicle.

result is consistent with rolipram’s reversal of Ab2535-induced decreases in escape latency and length of
swimming path.
The next day after the water-maze probe trial test
(i.e. 21 d after Ab25-35 infusions), the same rats were
tested for habituation latency, short-term memory,
and long-term memory using the passive avoidance
task, with daily rolipram treatment continued.
As shown in Fig. 3a, latency during the habituation
trial did not diﬀer in any of the groups [F(4, 55)=
0.149, p=0.963], indicating that all the rats had
similar responses to the test environment when electric shocks were not applied. The initial training
latency was not changed (data not shown). In the

retention test performed 3 h after training, latency
was not signiﬁcantly changed by drug treatment
[F(4, 55)=2.18, p=0.08 ; Fig. 3b], although Ab alone
tended to decrease retention, indicating short-term
memory was not altered. In contrast, retention
latency tested 24 h after initial training was changed
in a pattern similar to that in the water-maze
probe trial in rats treated with Ab25-35, in the presence or absence of rolipram [F(4, 55)=5.30, p=0.001 ;
Fig. 3c]. Post-hoc Newman–Keuls analyses indicated
that Ab25-35-treated rats exhibited a decrease in retention relative to vehicle controls (p<0.001) ; this was
reversed by rolipram (0.1–0.5 mg/kg), in particular at
the dose of 0.5 mg/kg (p<0.01), suggesting blockade
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Fig. 3. Eﬀects of rolipram on performance in the presence of Ab25-35 in the step-through passive avoidance test in rats.
(a) Latency to enter the dark compartment during habituation ; (b) retention tested 3 h after initial training ; (c) retention tested
24 h after initial training. While drug treatment did not alter latency during habituation or in the 3-h retention test, Ab25-35
administered 23 d before the test decreased the 24-h retention latency. This was reversed by rolipram at the higher dose of
0.5 mg/kg. Rolipram (0.1, 0.25, or 0.5 mg/kg) was injected (i.p.) once a day for 21–23 d during the passive avoidance test,
starting 24 h after microinfusion of Ab25-35 (10 mg/side) into bilateral CA1 subregions. Values shown are means¡S.E.M.
(n=12 per group) ; *** p<0.001 vs. vehicle controls (Veh+Veh) ; ## p<0.01 vs. Ab25-35+Veh.

by rolipram of Ab25-35-induced deﬁcit of long-term
memory.

pCREB (43 kDa)
GAPDH

Eﬀects of Ab25-35 on pCREB levels in the
hippocampus of rats treated with rolipram

Eﬀect of rolipram on Ab25-35-induced activation
of NF-kB p65
It has been shown in our recent study that Ab25-35
increases pro-inﬂammatory factors such as TNF-a (Lin
et al. 2009) ; this may cause changes in NF-kB, a
downstream target of TNF-a (Sanchez et al. 2005). To
clarify this, we examined the expression of NF-kB p65
in the hippocampus using the same tissues for
measuring pCREB. As shown in Fig. 5, levels of NF-kB

pCREB/GAPDH

To determine whether Ab25-35 decreased pCREB and
whether cAMP/CREB signalling contributed to the
reversal eﬀect of rolipram on Ab25-35-induced memory deﬁcit, we examined pCREB expression in the
hippocampus using the same rats, which were decapitated 24 h after the last behavioural test and 1 h
after the last rolipram injection (Li et al. 2011). Oneway ANOVA revealed signiﬁcant changes in pCREB
levels in the hippocampus in the treatment groups
[F(4, 10)=21.92, p<0.0001 ; Fig. 4]. Compared to
vehicle controls, Ab25-35 alone signiﬁcantly decreased
pCREB levels ; this eﬀect was reversed by rolipram at
doses of 0.1, 0.25, and 0.5 mg/kg, once daily for 24 d
(p<0.01 for 0.1 mg/kg and p<0.001 for the other two
doses). In contrast, expression of CREB was not altered
by the drug treatment (data not shown).

1.0
0.8

###

###

##

0.6
0.4

***

0.2
0.0
Veh
Veh

Veh

Rol 0.1

0.25

0.5

Aβ (10 µg/side)

Treatment and dose (mg/kg)
Fig. 4. Eﬀect of rolipram on expression of pCREB in the
hippocampus in rats treated with Ab25-35. Upper panel is
representative immunoblots of pCREB and GAPDH (inner
control) measured by Western blotting using respective
antibodies ; lower panel is quantiﬁcation of pCREB expressed
as the ratio of pCREB/GAPDH. Ab25-35 decreased pCREB in
the hippocampus, which was reversed by rolipram (0.1, 0.25,
or 0.5 mg/kg) in a dose-dependent manner. Starting 24 h
after CA1 microinfusions of Ab25-35 (10 mg/side), rolipram
was injected (i.p.) once a day for 24 d before sacriﬁce, which
was performed 24 h after the last behavioural test and 1 h
after rolipram treatment. Values shown are means¡S.E.M.
(n=3 per group) ; *** p<0.001 vs. vehicle controls
(Veh+Veh) ; ## p<0.01, ### p<0.001 vs. Ab25-35+Veh.

p65 expression in the hippocampus were changed by
drug treatment [F(4, 10)=12.27, p=0.0007]. Post-hoc
Newman–Keuls analyses indicated a signiﬁcant
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Reversal by rolipram of Ab25-35-induced
apoptotic eﬀects
Since Ab25-35 decreases neuronal cell viability via
increased apoptotic activity (Yao et al. 2007), we
examined expression of Bax, a pro-apoptotic protein
that induces rapid human neuronal cell death
(Bounhar et al. 2001), and Bcl-2, another cell deathassociated protein (Korsmeyer, 1992), to determine
whether apoptotic responses were involved in the
eﬀect of rolipram on Ab25-35-induced toxicity. As
shown in Fig. 6, both Bcl-2 and Bax were changed
by drug treatment [F(4, 10)=6.76, p=0.007 for Bcl-2
and F(4,10)=6.53, p=0.008 for Bax]. Post-hoc
Newman–Keuls analyses indicated that Ab25-35 decreased Bcl-2 (p<0.01 ; Fig. 6a) and increased Bax
(p<0.01 ; Fig. 6b) in the hippocampus, compared to
the vehicle controls ; these eﬀects were reversed by
rolipram in a dose-dependent manner (p<0.05 for all
except for 0.5 mg/kg in Bax, where p<0.01 ; Fig. 6).
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(b)
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Veh
Veh

increase in NF-kB p65 levels in rats treated with Ab2535+vehicle, compared to those treated with vehicle
(p<0.001) ; the eﬀect of Ab25-35 was reversed
by rolipram (0.1–0.5 mg/kg) in a dose-dependent
manner (p<0.05 for 0.1 and 0.25 mg/kg and p<0.01
for 0.5 mg/kg).

Rol 0.1

Treatment and dose (mg/kg)

bax/GAPDH

Fig. 5. Eﬀect of rolipram on Ab25-35-induced activation of
NF-kB p65 in the hippocampus in rats. Upper panel is
representative immunoblot of NF-kB p65 detected by
Western blotting ; lower panel is quantiﬁcation of NF-kB
p65 expressed as the ratio of NF-kB p65/GAPDH.
Ab25-35 increased NF-kB p65 in the hippocampus, this
was reversed by rolipram (0.1, 0.25, or 0.5 mg/kg) in a
dose-dependent manner. Administration of Ab25-35 and
rolipram was the same as that in the legend of Fig. 4.
Values shown are means¡S.E.M. (n=3 per group) ;
*** p<0.001 vs. vehicle controls (Veh+Veh) ; # p<0.05,
##
p<0.01 vs. Ab25-35+Veh.

Veh

Veh

Veh

Rol 0.1

0.25

0.5

Aβ (10 µg/side)

Treatment and dose (mg/kg)
Fig. 6. Eﬀect of rolipram on Ab25-35-induced changes in
Bcl-2 and Bax in the hippocampus in rats. (a) Rolipram
reversed Ab25-35-induced decreases in expression of the
anti-apoptotic mediator Bcl-2. (b) Rolipram reversed
Ab25-35-induced increases in expression of the apoptotic
mediator Bax. Upper panels are representative immunoblots
of (a) Bcl-2 and (b) Bax in the hippocampus measured by
Western blotting using respective antibodies ; lower panels
are respective quantiﬁcations. Administration of Ab25-35
and rolipram was the same as that in the legend of Fig. 4.
Values shown are means¡S.E.M. (n=3 per group) ;
** p<0.01 vs. vehicle controls (Veh+Veh) ; # p<0.05,
##
p<0.01 vs. Ab25-35+Veh.

Rolipram’s reversal of Ab1-42-induced changes
in pCREB, NF-kB p65, Bcl-2, and Bax in the
hippocampus
To verify the eﬀects of rolipram on Ab25-35-induced
changes in neuroinﬂammatory and apoptotic responses
in the hippocampus, we replicated the neurochemical
experiments by using Ab1-42, instead of Ab25-35.
In the measurement of pCREB, microinfusions of
Ab1-42 at 0.4 mg/side into bilateral CA1 subregions
decreased pCREB levels in the hippocampus (p<0.01),
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Fig. 7. Eﬀects of rolipram on Ab1-42-induced changes in pCREB, NF-kB p65, Bcl-2 and Bax in the hippocampus in rats treated
with Ab1-42. (a) Rolipram reversed Ab1-42-induced decreases in pCREB. (b) Rolipram reversed Ab1-42-induced decreases in
NF-kB p65. (c) Rolipram reversed Ab1-42-induced decreases in expression of Bcl-2. (d) Rolipram reversed Ab1-42-induced
increases in expression of Bax. For (a–d), upper panels are representative immunoblots of pCREB, NF-kB p65, Bcl-2, or Bax
and b-actin (inner control) measured by Western blotting using respective antibodies ; lower panels are quantiﬁcation of
corresponding proteins expressed as the ratio of pCREB, NF-kB p65, Bcl-2, or Bax divided by b-actin. Starting 24 h after CA1
microinfusions of Ab1-42 (0.4 mg/side), Ab42-1 (0.4 mg/side), or vehicle (1 ml/side), rolipram (0.5 mg/kg) was given (i.p.)
once a day for 14 d before sacriﬁce, which was performed 1 h after the last rolipram injection. Values shown are means¡S.E.M.
(n=3 per group) ; * p<0.05, ** p<0.01 vs. vehicle controls (Veh+Veh) ; # p<0.05, ## p<0.01 vs. Ab1-42+Veh.

while the reverse peptide Ab42-1 at the same dose
did not, relative to vehicle controls (Fig. 7a) ; this eﬀect
of Ab1-42 was reversed by rolipram (0.5 mg/kg, once
per day for 14 d ; p<0.01). The inter-group comparison
was signiﬁcant as revealed by one-way ANOVA
[F(3,8)=14.34, p<0.01]. In contrast, CREB levels
were not changed between groups (data not shown).
Inter-group changes similar to those in pCREB were
also observed in measurements of NF-kB p65
[F(3,8)=10.22, p=0.004], Bcl-2 [F(3,8)=8.73, p=0.007],
and Bax [F(3,8)=8.930, p=0.006]. More speciﬁcally,
compared to vehicle controls, CA1 microinfusions of
Ab1-42 (0.4 mg/side) increased NF-kB p65 (p<0.01,
Fig. 7b) and Bax (p<0.01, Fig. 7d) and decreased Bcl-2
(p<0.05, Fig. 7c) in the hippocampus ; these were all

reversed by rolipram [p<0.01, except for Bcl-2
(p<0.05) ; Fig. 7b–d]. In contrast, Ab42-1 did not alter
any of the measurements, which excluded the potential non-speciﬁc eﬀects of peptide.
Discussion
Ab peptides have been shown to activate the apoptotic
pathway (Koriyama et al. 2003 ; Mattson, 2004 ; Yao
et al. 2007), produce inﬂammatory responses (Abdi
et al. 2010 ; Di et al. 2010), inhibit hippocampal synaptic
plasticity (Vitolo et al. 2002 ; Zeng et al. 2010 ; Zhang
et al. 2006), and impair memory (Cheng et al. 2010 ;
Malm et al. 2006 ; Vollmar et al. 2010 ; Wang et al. 2010).
As the functional domain of full-length Ab peptides,
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the latter appears to require at least 0.5 mg/kg
rolipram to block Ab25-35-induced memory deﬁcit,
suggesting that the water-maze may be a more sensitive test for examining the interaction between Ab and
PDE4 inhibitors. A similar response diﬀerence has
been observed in rats with hypoxic damage to CA1,
which impairs memory performance in the watermaze, but not the passive avoidance test (Boissard et al.
1992).
It was noted that subchronic treatment with rolipram at the same dose slows down memory extinction
in the fear-conditioning test (Monti et al. 2006). Since
animals did not receive footshocks 3 h after initial
training in the passive avoidance test, extinction
learning might have existed in the 24-h retention
test. Thus, the eﬀect of rolipram on extinction learning
may contribute to its memory-enhancing action examined 24 h after training in the passive avoidance
test.
The eﬀect of rolipram appears to be independent of
sedation potentially produced by PDE4 inhibitors
(Griebel et al. 1991 ; Smith, 1990), given that rolipram at
the doses used did not alter swimming speed in the
water-maze probe trial test or latency to cross to the
dark compartment during habituation in the passive
avoidance task. The lack of the sedative property of
rolipram may be attributed to the strategy of rolipram
treatment, which, when given repeatedly and 1 h prior
to behavioural tests, is able to dissociate therapeutic
eﬀects from side-eﬀects such as sedation (Li et al. 2009,
2011).
Since the half-life of rolipram is short (1–3 h ;
Krause & Kuhne, 1988) and rolipram blockade of
scopolamine-induced memory impairment lasts for
only about 1 h (Zhang & O’Donnell, 2000), the reversal
eﬀect of rolipram on Ab25-35-induced memory deﬁcits
appears to result from chronic, rather than acute,
actions of rolipram. This is supported by the ﬁndings
that long-term memory-enhancing eﬀects of rolipram
are probably attributed to long-lasting neuronal
changes caused by chronic rolipram treatment, including increased phosphorylation of CREB and
neurogenesis in the hippocampus (Li et al. 2011 ;
Rutten et al. 2008). These adaptive changes, in particular in pCREB, may be one of the mechanisms
whereby rolipram reverses Ab-induced memory impairment.
It has been well established that rolipram increases
activation of brain cAMP/CREB signalling (Barad et al.
1998 ; Li et al. 2011 ; Monti et al. 2006 ; Nakagawa
et al. 2002 ; Zhang et al. 2002, 2004), which is impaired
in AD (Satoh et al. 2009). However, it is not clear
whether cAMP/CREB signalling is important in the
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Ab25-35 is toxic to neurons and contributes to
Ab-induced properties of neurotoxicity, oxidation,
inﬂammation, and apoptosis (Ahn et al. 2006 ; Um et al.
2006). Here we demonstrate that a single microinfusion of aged Ab25-35 into bilateral CA1 subregions
in the hippocampus produced deﬁcits of learning and
memory accompanied by inﬂammatory and apoptotic
responses in the hippocampus ; it also concurrently
decreased pCREB levels in this brain region. These
eﬀects of Ab25-35 were reversed by repeated treatment with rolipram, which increased pCREB in the
hippocampus. Similar eﬀects were also observed
when Ab25-35 was replaced with Ab1-42, but not the
inactive peptide Ab42-1. These results suggest that
inhibition of PDE4 reverses Ab-induced cognitive
deﬁcits, which are contributed, at least partially, by
neuronal inﬂammation and apoptosis mediated by
cAMP/CREB signalling.
Both Morris water-maze and passive avoidance
tests appear to be sensitive to Ab treatment (Cheng
et al. 2010 ; Mouri et al. 2006). Microinfusions of
Ab25-35 into bilateral CA1 subregions of the hippocampus impaired learning ability and long-term
memory, as demonstrated by decreased 24-h retention
in the passive avoidance test, and prolonged escape
latency in the acquisition trials, and decreased exploration in the target quadrant in the probe trial
performed 24 h after the last training trial in the watermaze test. These results are supported by ﬁndings
from previous studies, in which Ab25-35 produces
memory deﬁcits in a variety of animal tasks
(Cheng et al. 2006, 2010 ; Holscher et al. 2007 ; Tohda
et al. 2004). Consistent with these, microinfusions of
Ab1-42 into the hippocampus or lateral ventricle in
the brain impairs memory (Christensen et al. 2008 ;
Malm et al. 2006 ; Yamada et al. 1999), suggesting
that central administration of Ab is a reliable model of
AD for testing cognition, including learning and
memory.
It has been established that rolipram alone enhances
memory via activation of cAMP/CREB signalling
(Barad et al. 1998 ; Li et al. 2011). Consistent with
the memory-enhancing eﬀect of rolipram, Ab25-35induced deﬁcits of learning and memory were reversed by repeated treatment with rolipram. This is
supported by ﬁndings in the study using APP/PS1
transgenic mice (Gong et al. 2004) and in our previous
study, in which rolipram administered at 0.5 mg/kg
for 3 wk reverses Ab25-35-induced memory deﬁcits
using the same memory paradigms (Cheng et al. 2010).
We lowered the dose of rolipram to 0.1 mg/kg and
still observed a potent memory-enhancing eﬀect in
the water-maze test, but not passive avoidance test ;
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degenerative disorders, including AD (Hardy &
Selkoe, 2002 ; Rojo et al. 2008). Increases in cAMP levels
inhibit pro-inﬂammatory (Dastidar et al. 2009 ; Hoyle,
2010) and apoptotic responses (Kim et al. 2010 ; Naderi
et al. 2009). PDE4 inhibitors such as rolipram increase
intracellular cAMP levels and reduce inﬂammatory
cytokines such as TNF-a (Taguchi et al. 1999) and its
downstream target NF-kB (Sanchez et al. 2005), which
is induced by Ab (Gong et al. 2011). Our results provide an integration of these ﬁndings, i.e. rolipram
reversed not only Ab25-35- or Ab1-42-induced deﬁcits
of pCREB, but also the Ab-induced inﬂammatory
response, as indicated by increased NF-kB p65 in the
hippocampus. This is consistent with the negative
regulation of NF-kB signalling by cAMP (Parry &
Mackman, 1997). Therefore, rolipram inhibits inﬂammatory responses induced by Ab25-35 or Ab1-42 most
likely via attenuating activation of NF-kB p65
mediated by cAMP/CREB signalling. In addition, the
anti-inﬂammatory eﬀect of rolipram paralleled the
improvement of Ab25-35-induced memory deﬁcits,
suggesting that neuroinﬂammation may contribute to
memory impairment produced by Ab.
Since NF-kB signalling enhances apoptosis (Tusi
et al. 2010) and inhibition of NF-kB not only protracts
inﬂammatory responses but also prevents apoptosis
(Lawrence et al. 2001), it was of interest to know
whether rolipram altered Ab-induced apoptotic
responses. A variety of molecules have been shown to
be involved in the cellular apoptosis machinery ; these
include p53 (Haupt et al. 1997 ; Ryan et al. 2001), the
Bcl-2 family (Dimmeler et al. 1999 ; Li & Dou, 2000),
XIAP (Yang et al. 2000), caspase members (Suzuki et al.
2001), and p38 MAP kinase (Wang et al. 2005). Of
these, the Bcl-2 family members are the most important molecules in regulating apoptosis. They can be
divided into anti-apoptotic members, such as Bcl-2,
Bcl-xl, and Bcl-w, and pro-apoptotic members, such as
Bax and Bak (Borner, 2003). It has been considered that
the ratio of Bcl-2/Bax is crucial in the regulation
of apoptosis (Borner, 2003 ; Korsmeyer et al. 1995).
Microinfusions of either Ab25-35 or Ab1-42 decreased
Bcl-2 and increased Bax, leading to reduction of the
Bcl-2/Bax ratio and increases in apoptotic responses in
the hippocampus. Rolipram, at the same doses that
blocked Ab-induced deﬁcits of memory (for Ab25-35)
and cAMP/CREB signalling and activation of NF-kB
signalling, also reversed the Ab-induced decrease
in the Bcl-2/Bax ratio (i.e. decreases in Bcl-2 and
increases in Bax). The results are in agreement with
those indicating that activation of CREB up-regulates
Bcl-2 (Karsan et al. 1997) and that cAMP-dependent
protein kinases regulate apoptosis by phosphorylation
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reversal eﬀect of rolipram on memory deﬁcits associated with AD. In the present study, we demonstrated that chronic treatment with rolipram, at the
same doses blocking spatial memory impairment in
the water-maze test, reversed Ab25-35-induced decreases in hippocampal pCREB. In addition, the eﬀect
of rolipram on pCREB was highly correlated with that
on memory performance. The reversal eﬀect of rolipram on pCREB in the hippocampus was veriﬁed by
using Ab1-42, which is supported by ﬁndings that
rolipram blocks Ab1-42-induced inhibition of pCREB
in hippocampal neurons (Vitolo et al. 2002). These results are consistent with our previous ﬁnding that
pCREB is involved in rolipram reversal of Ab1-40induced memory deﬁcits (Cheng et al. 2010), suggesting an important role of cAMP/CREB signalling in the
mediation of the memory-enhancing eﬀect of rolipram
in the animal model of AD.
It was noted that under certain conditions, CREB
phosphorylation can be induced rapidly (within
5–10 min) and transiently (lasting 1–2 h or even
shorter ; Cammarota et al. 2001 ; Sala et al. 2000 ;
Shaywitz & Greenberg, 1999). This raised the concern
about whether the reversal eﬀect of rolipram was due
to repeated treatment or ﬁnal (acute) treatment and
the question about the signiﬁcance of changes in
pCREB measured 1 h after rolipram treatment.
However, it is important to note that, while rolipram
at high doses such as 3 mg/kg administered acutely
increases cAMP and pCREB in the hippocampus
(Giorgi et al. 2004 ; Monti et al. 2006), acute treatment
with rolipram at the same dose (1.25 mg/kg) as used
in the present study does not alter hippocampal
pCREB (Nakagawa et al. 2002). Instead, chronic treatment with rolipram is usually required to produce
behavioural and neurochemical alterations, including
those in pCREB and memory (Li et al. 2009, 2011 ;
Monti et al. 2006 ; Nakagawa et al. 2002 ; Zhang et al.
2002). In addition, rolipram is a highly selective,
prototypical inhibitor of PDE4 (Zhang et al. 2005).
Repeated treatment with rolipram increases cAMP in
the hippocampus examined 1 h after the last rolipram
injection (Li et al. 2009). Cyclic AMP-activated PKA
could induce persistent phosphorylation of CREB
(Sala et al. 2000). Therefore, the reversal eﬀect of rolipram on pCREB may be attributed to repeated, rather
than acute treatment with rolipram. Rolipram reverses
the eﬀects of Ab most likely via cAMP/CREB signalling given that microinfusions of Ab25-35 or Ab1-42 in
CA1 decreased pCREB.
Studies have demonstrated a coincidence of
inﬂammatory damage and apoptotic neuronal death
during the development or progression of neuro-
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